Mustang Bio CFIUS review for asset sale to uBrigene enters investigation phase; decision by Feb 12, 2024

MUSTANG BIO, INC.

CFIUS began a 45-day investigation after the initial review period expired on Dec 28, 2023 without conclusion.
CFIUS must complete its investigation no later than February 12, 2024.
Transaction involves sale of Mustang's Worcester cell processing facility and assets to uBrigene, a Chinese CDMO.
CFIUS clearance was not a condition to closing the transaction.
The parties previously withdrew and re-filed their CFIUS notice on Nov 13, 2023 to allow more review time.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.